These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 24377525)
1. FBW7 upregulation enhances cisplatin cytotoxicity in non- small cell lung cancer cells. Yu HG; Wei W; Xia LH; Han WL; Zhao P; Wu SJ; Li WD; Chen W Asian Pac J Cancer Prev; 2013; 14(11):6321-6. PubMed ID: 24377525 [TBL] [Abstract][Full Text] [Related]
2. FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein. Song Y; Zhou X; Bai W; Ma X Tumour Biol; 2015 Jun; 36(6):4197-202. PubMed ID: 25586348 [TBL] [Abstract][Full Text] [Related]
3. FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition. Yu J; Zhang W; Gao F; Liu YX; Chen ZY; Cheng LY; Xie SF; Zheng SS Hepatobiliary Pancreat Dis Int; 2014 Apr; 13(2):184-91. PubMed ID: 24686546 [TBL] [Abstract][Full Text] [Related]
4. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer. Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751 [TBL] [Abstract][Full Text] [Related]
5. FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein. Zhang Y; Zhang X; Ye M; Jing P; Xiong J; Han Z; Kong J; Li M; Lai X; Chang N; Zhang J; Zhang J Cancer Lett; 2018 Apr; 419():75-83. PubMed ID: 29355657 [TBL] [Abstract][Full Text] [Related]
6. MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7. Xiang J; Hang JB; Che JM; Li HC Int J Clin Exp Pathol; 2015; 8(8):9147-53. PubMed ID: 26464659 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2. Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840 [TBL] [Abstract][Full Text] [Related]
8. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells. He Y; Xie H; Yu P; Jiang S; Wei L Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523 [TBL] [Abstract][Full Text] [Related]
10. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway. Zhang Y; Zhang Q; Chen H; Wang C Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. Xu Y; Sengupta T; Kukreja L; Minella AC J Biol Chem; 2010 Nov; 285(45):34439-46. PubMed ID: 20826802 [TBL] [Abstract][Full Text] [Related]
13. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113 [TBL] [Abstract][Full Text] [Related]
14. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs. Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783 [TBL] [Abstract][Full Text] [Related]
15. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells. Ba Z; Zhou Y; Yang Z; Xu J; Zhang X J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188 [TBL] [Abstract][Full Text] [Related]
16. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954 [TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor functions of FBW7 in cancer development and progression. Wang Z; Inuzuka H; Zhong J; Wan L; Fukushima H; Sarkar FH; Wei W FEBS Lett; 2012 May; 586(10):1409-18. PubMed ID: 22673505 [TBL] [Abstract][Full Text] [Related]
18. E3 ubiquitin ligase Hakai regulates cell growth and invasion, and increases the chemosensitivity to cisplatin in non‑small‑cell lung cancer cells. Liu Z; Wu Y; Tao Z; Ma L Int J Mol Med; 2018 Aug; 42(2):1145-1151. PubMed ID: 29786107 [TBL] [Abstract][Full Text] [Related]
19. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway. Xia Y; He Z; Liu B; Wang P; Chen Y Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239 [TBL] [Abstract][Full Text] [Related]
20. Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer. Xu K; Liu B; Liu Y Mol Med Rep; 2015 Jul; 12(1):995-1001. PubMed ID: 25683840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]